A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
NCT ID: NCT01218204
Last Updated: 2019-07-16
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
287 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-09-14
Study Completion Date
2011-06-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
NCT01370603
Hypercholesterolemia
COMPLETED
PHASE3
Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients
NCT02364258
Dyslipidemia
COMPLETED
PHASE1
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
NCT01370590
Hypercholesterolemia
COMPLETED
PHASE3
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
NCT00782184
Hypercholesterolemia
COMPLETED
PHASE3
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
NCT03882996
Hypercholesterolemia
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This compound has been studied in healthy subjects and subjects with type II diabetes and is now being studied in subjects with dyslipidemia. Because many patients with dyslipidemia are on statins, it is important to study how GSK1292263 behaves when taken with a potent statin, atorvastatin. The cholesterol lowering drug, ezetimibe, is included for comparison.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dyslipidaemias
Dyslipidemias
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A Run-in
Subjects on stable 40mg atorvastatin \> 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
Group Type
OTHER
80mg atorvastatin
Intervention Type
DRUG
80mg
Part A Co-Dosing 800mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
800mg GSK1292263
Intervention Type
DRUG
800mg
Part B Washout
Washout for 4 weeks
Group Type
OTHER
Washout
Intervention Type
OTHER
No interventions - washout period
Part B Run-in 10mg atorvastatin
Dosing for 4 weeks
Group Type
ACTIVE_COMPARATOR
10mg atorvastatin
Intervention Type
DRUG
10mg
Part B Run-in 80mg atorvastatin
Dosing for 4 weeks
Group Type
ACTIVE_COMPARATOR
80mg atorvastatin
Intervention Type
DRUG
80mg
Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
10mg atorvastatin
Intervention Type
DRUG
10mg
Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
300mg GSK1292263
Intervention Type
DRUG
300mg
Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
10mg atorvastatin
Intervention Type
DRUG
10mg
800mg GSK1292263
Intervention Type
DRUG
800mg
Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe
Dosing for 14 days
Group Type
EXPERIMENTAL
10mg atorvastatin
Intervention Type
DRUG
10mg
10mg ezetimibe
Intervention Type
DRUG
10mg
Part B Dosing 100mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
100mg GSK1292263
Intervention Type
DRUG
100mg
Part B Dosing 300mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
300mg GSK1292263
Intervention Type
DRUG
300mg
Part B Dosing 800mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
800mg GSK1292263
Intervention Type
DRUG
800mg
Part B Dosing Placebo GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
GSK1292263 Placebo
Intervention Type
DRUG
Placebo
Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263
Dosing for 14 days
Group Type
EXPERIMENTAL
80mg atorvastatin
Intervention Type
DRUG
80mg
Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)
Dosing for 14 days
Group Type
EXPERIMENTAL
GSK1292263 Placebo
Intervention Type
DRUG
Placebo
Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)
Dosing for 14 days
Group Type
EXPERIMENTAL
10mg atorvastatin
Intervention Type
DRUG
10mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
10mg atorvastatin
10mg
Intervention Type
DRUG
80mg atorvastatin
80mg
Intervention Type
DRUG
GSK1292263 Placebo
Placebo
Intervention Type
DRUG
100mg GSK1292263
100mg
Intervention Type
DRUG
300mg GSK1292263
300mg
Intervention Type
DRUG
800mg GSK1292263
800mg
Intervention Type
DRUG
10mg ezetimibe
10mg
Intervention Type
DRUG
Washout
No interventions - washout period
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Lipitor
Lipitor
Zetia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy adult males and females of non-child-bearing-potential, aged 18-75 years who is capable of giving informed consent.
* A female subject is eligible to participate if she is of:
* Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases, a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \<40 pg/ml (\<140 pmol/L) is confirmatory in the absence of a clear post-menopausal history.
* Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study.
* Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until seven days following the last dose.
* Body weight \> 50 kg (110 pounds) and body mass index (BMI) between 19.0 and 39.0 (inclusive).
* Part A: (i) Subjects who are on 80mg or 40mg atorvastatin for \>= 4 weeks and are tolerating the drug well, or (ii) Subjects not on lipid-modifying therapy who have a fasting low density lipoprotein cholesterol (LDLc) \>= 130mg/dL.
* In Part B at Screening: Subjects who are on statins or Vytorin treatment for \>= 4 weeks.
* Part B at the end of the 4 week washout: Subjects who have a fasting LDL cholesterol of \>=120mg/dL and \<=180mg/dL and fasting triglycerides of \>=100mg/dL and \<=400mg/dL.
* Part B at the end of the 4 week run-in on atorvastatin: Subjects who are tolerating well atorvastatin 10mg or 80mg (as determined by the Investigator).
* Part B: Subjects must be willing to discontinue statins or Vytorin for the duration of the study.
* Liver enzymes, AST and ALT \< 2x upper limit of normal (ULN); alkaline phosphatase and bilirubin =\< 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). Subjects with Gilbert's syndrome are allowed to participate in the study.
* Average QTcB or QTcF \< 450msec; or QTc \< 480msec in subjects with right bundle branch block.
* A female subject is eligible to participate if she is of:
* Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases, a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \<40 pg/ml (\<140 pmol/L) is confirmatory in the absence of a clear post-menopausal history.
* Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study.
* Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until seven days following the last dose.
* Body weight \> 50 kg (110 pounds) and body mass index (BMI) between 19.0 and 39.0 (inclusive).
* Part A: (i) Subjects who are on 80mg or 40mg atorvastatin for \>= 4 weeks and are tolerating the drug well, or (ii) Subjects not on lipid-modifying therapy who have a fasting low density lipoprotein cholesterol (LDLc) \>= 130mg/dL.
* In Part B at Screening: Subjects who are on statins or Vytorin treatment for \>= 4 weeks.
* Part B at the end of the 4 week washout: Subjects who have a fasting LDL cholesterol of \>=120mg/dL and \<=180mg/dL and fasting triglycerides of \>=100mg/dL and \<=400mg/dL.
* Part B at the end of the 4 week run-in on atorvastatin: Subjects who are tolerating well atorvastatin 10mg or 80mg (as determined by the Investigator).
* Part B: Subjects must be willing to discontinue statins or Vytorin for the duration of the study.
* Liver enzymes, AST and ALT \< 2x upper limit of normal (ULN); alkaline phosphatase and bilirubin =\< 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). Subjects with Gilbert's syndrome are allowed to participate in the study.
* Average QTcB or QTcF \< 450msec; or QTc \< 480msec in subjects with right bundle branch block.
Exclusion Criteria
* A medical history of the following:
* Clinical or angiographic cardiovascular disease, including history or current evidence of coronary heart disease, heart failure, cerebrovascular disease (including stroke and transient ischemic attack \[mini-stroke\]), peripheral vascular disease. Subjects pending diagnostic procedures for any of those conditions at the time of screening will not be eligible for participation.
* Homozygous familial hypercholesterolemia or family history of familial hypercholesterolemia (Part B only). Note: Subjects with heterozygous familial hypercholesterolemia on 80mg atorvastatin who are tolerating this drug well and fulfill the other eligibility criteria may participate in Part A only.
* History of recurrent or unexplained muscle aches (e.g., fibromyalgia), myopathy or myositis, whether or not it is related to treatment with statins or other lipid modifying drugs.
* Renal impairment as defined by a calculated glomerular filtration rate \< 60 mL/min
* History of diabetes mellitus, or history of post-prandial and/or random blood glucose \> 200 mg/dl or fasting glucose \> 125 mg/dL or currently taking diabetes medications to manage fasting glucose levels (e.g., thiazolidinediones, sulfonylureas, insulin, metformin).
* History of pancreatitis within 10 years of screening.
* Any concurrent serious illness (e.g., severe chronic obstructive pulmonary disease, sleep apnea, history of malignancy other than skin cancer within 5 years of initial diagnosis or with evidence of recurrence) that may interfere with a subject from completing the study.
* Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
* Active peptic ulcer disease and/or history of peptic ulcer disease or gastrointestinal bleeding within 12 months prior to screening.
* History of kidney stones within 10 years of screening.
* History of uncorrected thyroid dysfunction or an abnormal thyroid function test assessed by thyroid stimulating hormone (TSH) at Screening. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 3 months prior to screening and who have a screening TSH within the normal range may participate.)
* Symptomatic cholelithiasis or obstructive or inflammatory gallbladder disease within 3 months prior to screening.
* Gastrointestinal disease that could affect fat or bile acid absorption, or the pharmacokinetics or pharmacodynamics of the study drugs, including inflammatory bowel disease, chronic diarrhea, Crohn's disease or malabsorption syndromes within the past year.
* Gastrointestinal surgery that may affect the pharmacokinetics or pharmacodynamics of the study drugs.
Note: Subjects may be enrolled in the study if they have had a cholecystectomy three or more months before the time of screening and are stable and asymptomatic.
* Subjects taking ezetimibe monotherapy, fibrates, bile acid binding resins, nicotinic acid or fat absorption inhibitors are not eligible for Parts A and B.
* For females a hemoglobin \< 11.5g/dL, and for males a hemoglobin \< 12.5g/dL.
* Current inadequately controlled hypertension (blood pressure \>= 160mmHg systolic or \>= 100mmHg diastolic at screening). If blood pressure medication is changed as a result of screening, blood pressure will be re-measured after 6 weeks and must again meet these criteria.
* Significant electrocardiogram (ECG) abnormalities, defined as follows:
Heart Rate \< 50 and \>100bpm PR Interval \<120 and \> 220ms QRS duration \< 70 and \>120ms QTC Interval (Bazett) \> 450ms Or, has clinically significant rhythm abnormalities identified during 24-hour screening Holter assessment. Subjects with left bundle branch block are excluded from the study. Subjects with partial right bundle branch block may be considered for inclusion following consultation with the GlaxoSmithKline (GSK) Medical Monitor. Subjects with Wolf-Parkinson-White (WPW) syndrome are excluded from the study.
* Creatinine phosphokinase (CPK) \>= 2x ULN at screening.
* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
* A positive test for HIV antibody.
* The subject has a positive pre-study drug-of-abuse screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
* History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of \>14 drinks/week for men or \>7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits.
* Subjects will be excluded if they require treatment with systemic corticosteroids.
* Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to dosing.
* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
* History of sensitivity or untoward reaction to the study medications (GSK1292263, atorvastatin or ezetimibe), or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
* History of intolerance to statins.
* Any change in concomitant medication (including multivitamins, herbal remedies, dietary supplements, and over-the-counter medication) within six weeks prior to screening that is not approved by GSK.
* On a diet that may affect study outcomes, or any change in diet, exercise habits or smoking status within six weeks prior to screening or planned change during study (e.g., new exercise program) other than that in the dietary instructions in the Study Procedures Manual.
* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
* Where participation in study would result in donation of blood in excess of approximately 500mL within a 56 day period.
* Subject is mentally or legally incapacitated.
* Unwillingness or inability to follow the procedures outlined in the protocol.
* Pregnant females as determined by positive urine hCG test at screening or prior to dosing.
* Lactating females.
* History of sensitivity to heparin or heparin-induced thrombocytopenia.
* Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
* Unwilling to abstain from caffeine-or xanthine-containing products from Day -2 until Day 15.
* Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study.
* Clinical or angiographic cardiovascular disease, including history or current evidence of coronary heart disease, heart failure, cerebrovascular disease (including stroke and transient ischemic attack \[mini-stroke\]), peripheral vascular disease. Subjects pending diagnostic procedures for any of those conditions at the time of screening will not be eligible for participation.
* Homozygous familial hypercholesterolemia or family history of familial hypercholesterolemia (Part B only). Note: Subjects with heterozygous familial hypercholesterolemia on 80mg atorvastatin who are tolerating this drug well and fulfill the other eligibility criteria may participate in Part A only.
* History of recurrent or unexplained muscle aches (e.g., fibromyalgia), myopathy or myositis, whether or not it is related to treatment with statins or other lipid modifying drugs.
* Renal impairment as defined by a calculated glomerular filtration rate \< 60 mL/min
* History of diabetes mellitus, or history of post-prandial and/or random blood glucose \> 200 mg/dl or fasting glucose \> 125 mg/dL or currently taking diabetes medications to manage fasting glucose levels (e.g., thiazolidinediones, sulfonylureas, insulin, metformin).
* History of pancreatitis within 10 years of screening.
* Any concurrent serious illness (e.g., severe chronic obstructive pulmonary disease, sleep apnea, history of malignancy other than skin cancer within 5 years of initial diagnosis or with evidence of recurrence) that may interfere with a subject from completing the study.
* Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
* Active peptic ulcer disease and/or history of peptic ulcer disease or gastrointestinal bleeding within 12 months prior to screening.
* History of kidney stones within 10 years of screening.
* History of uncorrected thyroid dysfunction or an abnormal thyroid function test assessed by thyroid stimulating hormone (TSH) at Screening. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 3 months prior to screening and who have a screening TSH within the normal range may participate.)
* Symptomatic cholelithiasis or obstructive or inflammatory gallbladder disease within 3 months prior to screening.
* Gastrointestinal disease that could affect fat or bile acid absorption, or the pharmacokinetics or pharmacodynamics of the study drugs, including inflammatory bowel disease, chronic diarrhea, Crohn's disease or malabsorption syndromes within the past year.
* Gastrointestinal surgery that may affect the pharmacokinetics or pharmacodynamics of the study drugs.
Note: Subjects may be enrolled in the study if they have had a cholecystectomy three or more months before the time of screening and are stable and asymptomatic.
* Subjects taking ezetimibe monotherapy, fibrates, bile acid binding resins, nicotinic acid or fat absorption inhibitors are not eligible for Parts A and B.
* For females a hemoglobin \< 11.5g/dL, and for males a hemoglobin \< 12.5g/dL.
* Current inadequately controlled hypertension (blood pressure \>= 160mmHg systolic or \>= 100mmHg diastolic at screening). If blood pressure medication is changed as a result of screening, blood pressure will be re-measured after 6 weeks and must again meet these criteria.
* Significant electrocardiogram (ECG) abnormalities, defined as follows:
Heart Rate \< 50 and \>100bpm PR Interval \<120 and \> 220ms QRS duration \< 70 and \>120ms QTC Interval (Bazett) \> 450ms Or, has clinically significant rhythm abnormalities identified during 24-hour screening Holter assessment. Subjects with left bundle branch block are excluded from the study. Subjects with partial right bundle branch block may be considered for inclusion following consultation with the GlaxoSmithKline (GSK) Medical Monitor. Subjects with Wolf-Parkinson-White (WPW) syndrome are excluded from the study.
* Creatinine phosphokinase (CPK) \>= 2x ULN at screening.
* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
* A positive test for HIV antibody.
* The subject has a positive pre-study drug-of-abuse screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
* History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of \>14 drinks/week for men or \>7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits.
* Subjects will be excluded if they require treatment with systemic corticosteroids.
* Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to dosing.
* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
* History of sensitivity or untoward reaction to the study medications (GSK1292263, atorvastatin or ezetimibe), or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
* History of intolerance to statins.
* Any change in concomitant medication (including multivitamins, herbal remedies, dietary supplements, and over-the-counter medication) within six weeks prior to screening that is not approved by GSK.
* On a diet that may affect study outcomes, or any change in diet, exercise habits or smoking status within six weeks prior to screening or planned change during study (e.g., new exercise program) other than that in the dietary instructions in the Study Procedures Manual.
* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
* Where participation in study would result in donation of blood in excess of approximately 500mL within a 56 day period.
* Subject is mentally or legally incapacitated.
* Unwillingness or inability to follow the procedures outlined in the protocol.
* Pregnant females as determined by positive urine hCG test at screening or prior to dosing.
* Lactating females.
* History of sensitivity to heparin or heparin-induced thrombocytopenia.
* Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
* Unwilling to abstain from caffeine-or xanthine-containing products from Day -2 until Day 15.
* Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Anniston, Alabama, United States
Site Status
GSK Investigational Site
Chula Vista, California, United States
Site Status
GSK Investigational Site
Stockton, California, United States
Site Status
GSK Investigational Site
Jacksonville, Florida, United States
Site Status
GSK Investigational Site
Miami, Florida, United States
Site Status
GSK Investigational Site
Miami, Florida, United States
Site Status
GSK Investigational Site
Port Orange, Florida, United States
Site Status
GSK Investigational Site
St. Petersburg, Florida, United States
Site Status
GSK Investigational Site
Chicago, Illinois, United States
Site Status
GSK Investigational Site
Chicago, Illinois, United States
Site Status
GSK Investigational Site
Louisville, Kentucky, United States
Site Status
GSK Investigational Site
Kalamazoo, Michigan, United States
Site Status
GSK Investigational Site
Minneapolis, Minnesota, United States
Site Status
GSK Investigational Site
Berlin, New Jersey, United States
Site Status
GSK Investigational Site
Cincinnati, Ohio, United States
Site Status
GSK Investigational Site
Oklahoma City, Oklahoma, United States
Site Status
GSK Investigational Site
Eugene, Oregon, United States
Site Status
GSK Investigational Site
Spartanburg, South Carolina, United States
Site Status
GSK Investigational Site
San Antonio, Texas, United States
Site Status
GSK Investigational Site
San Antonio, Texas, United States
Site Status
GSK Investigational Site
Renton, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
113779
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
NCT01779453
COMPLETED
PHASE2
Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
NCT00689442
COMPLETED
PHASE2
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
NCT00418834
COMPLETED
PHASE3
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
NCT01236430
COMPLETED
PHASE1
Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients
NCT03611010
COMPLETED
PHASE2
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
NCT00463606
COMPLETED
PHASE3
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
NCT02659397
COMPLETED
PHASE2
Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
NCT00889226
COMPLETED
PHASE4
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
NCT00639158
COMPLETED
PHASE3
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
NCT06238466
ACTIVE_NOT_RECRUITING
PHASE1
Drug-Drug Interaction Study Between Colchicine and Atorvastatin
NCT00960323
COMPLETED
PHASE1
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
NCT00289900
COMPLETED
PHASE3
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)
NCT06699355
COMPLETED
PHASE1
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)
NCT00653796
COMPLETED
PHASE4
An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)
NCT03867110
COMPLETED
PHASE3
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
NCT00276484
COMPLETED
PHASE3
Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)
NCT03882892
COMPLETED
PHASE3
CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers
NCT02288338
COMPLETED
PHASE1
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
NCT01859455
COMPLETED
PHASE1
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
NCT00276458
COMPLETED
PHASE3
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
NCT00535405
COMPLETED
PHASE3
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
NCT00690443
COMPLETED
PHASE2
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391
NCT02451098
COMPLETED
PHASE3
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
NCT02714569
COMPLETED
PHASE1
Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia
NCT02035215
UNKNOWN
PHASE3